NCT05107193 2022-11-08
Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)
Boehringer Ingelheim
No longer available
Clinical Trials
4 trialsNCT01931306 2018-11-14
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Approved for marketing
NCT01649284 2016-11-30
Afatinib Expanded Access Program
Boehringer Ingelheim
Approved for marketing
NCT01209650 2016-11-10
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
Boehringer Ingelheim
Approved for marketing